Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. Show more

Location: 890 Winter Street, Waltham, MA, 02451, United States | Website: https://upstreambio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

947.2M

52 Wk Range

$5.14 - $29.46

Previous Close

$17.57

Open

$17.83

Volume

374,000

Day Range

$16.79 - $18.00

Enterprise Value

555.2M

Cash

393.6M

Avg Qtr Burn

-28.49M

Insider Ownership

14.81%

Institutional Own.

90.42%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Verekitug Details Chronic Obstructive Pulmonary Disease (COPD)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Verekitug Details Severe asthma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Verekitug Details Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.